PrintFriendly
Featured News
|
Friday, February 1, 2019  Researchers from the University of California (UC) Davis have been investigating whether two genetically engineered cell types could be customized for long term therapeutic benefit in individuals with hemophilia A. |
|
Thursday, January 24, 2019  Thirteen runners, nine states, thirteen miles, and one great cause: Team NHF are avid athletes who are excited to run on behalf of the bleeding disorders community. |
|
Friday, January 18, 2019  The acquisition was approved on December 5th, 2018. |
|
Friday, January 4, 2019  Linda Gammage, MSW, LCSW, passed away on December 26, 2018. |
|
Monday, December 17, 2018  The court ruled that the entirety of the ACA is unconstitutional because the 2017 tax reform law eliminated the individual mandate tax penalty. |
|
Monday, December 17, 2018  Sangamo announced it has treated the first patient in a Phase 1/2 clinical trial evaluating SB-FIX, the company’s investigational gene therapy for patients with hemophilia B. |
|
Monday, December 17, 2018  Seven ways your gift to NHF will support people with bleeding disorders. |
|
Friday, December 14, 2018  The data presented was from 33 patients who have completed five years of treatment with Jivi®. |
|
Friday, December 14, 2018  The data from both studies confirmed the safety and sustained efficacy of Eloctate ® and Alprolix ® over four years of treatment. |
|
Wednesday, December 12, 2018  NHF's research grants support a variety of disciplines and levels of expertise. |